Cabaletta Bio Gets FDA OK to Study CABA-201 in Generalized Myasthenia Gravis
By Colin Kellaher
Cabaletta Bio has won Food and Drug Administration authorization to launch a Phase 1/2 study of its CABA-201 investigational therapy in patients with the rare autoimmune disease generalized myasthenia gravis.
The Philadelphia clinical-stage biotechnology company on Monday said the green light expands the clinical development of its lead product candidate beyond rheumatology into neurology, adding that it plans to initiate a study across two parallel patient cohorts based on autoantibody status.
Cabaletta--which previously received FDA approvals to study CABA-201 in lupus, myositis and systemic sclerosis--said it is on track to deliver initial clinical data from patients with lupus and/or myositis in the first half of 2024.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 06, 2023 07:40 ET (12:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
What I Hope My 14-Year-Old Learned at Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Amazon Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Dividend Stocks
-
3 Stocks With High Dividend Yields That Warren Buffett Likes
-
How to Invest Like Warren Buffett
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?